UPDATED PROGRESSION-FREE SURVIVAL AND DEPTH OF RESPONSE IN IKEMA, A RANDOMIZED PHASE 3 TRIAL OF ISATUXIMAB, CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA M Capra; P Moreau; M Dimopoulos; J Mikhael; K Yong; T Facon; R Hajek; I Spicka; F Casca; S Macé; M Risse; T Martin;

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: IKEMA SUBGROUP ANALYSIS A Maiolino; R Hajek; T Jelinek; P Moreau; T Martin; L Pour; G Mikala; A Symeonidis; S Bringhen; A Rawlings; ML Risse; H Vande-Velde; I Spicka;

DARATUMUMAB + BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (DVRD) VS VRD IN TRANSPLANT-INELIGIBLE (TIE)/TRANSPLANT-DEFERRED (TD) NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): PHASE 3 CEPHEUS TRIAL CYTOGENETIC SUBGROUP ANALYSIS NJ Bahlis; SZ Usmani; T Facon; S Zweegman; C Venner; M Braunstein; L Pour; J Marti; A Maiolino; V Hungria;